Lucid Diagnostics (NASDAQ:LUCD) Stock Price Down 0.5% – Here’s What Happened

Lucid Diagnostics Inc. (NASDAQ:LUCD) was down 0.5% during trading on Monday . The company traded as low as $0.83 and last traded at $0.84. Approximately 111,094 shares changed hands during trading, a decline of 67% from the average daily volume of 333,416 shares. The stock had previously closed at $0.85.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on LUCD shares. Cantor Fitzgerald dropped their target price on Lucid Diagnostics from $3.00 to $2.00 and set an “overweight” rating on the stock in a report on Friday, November 15th. Needham & Company LLC reiterated a “buy” rating and issued a $2.50 price objective on shares of Lucid Diagnostics in a research note on Thursday, November 14th. Ascendiant Capital Markets decreased their target price on shares of Lucid Diagnostics from $7.25 to $7.00 and set a “buy” rating for the company in a research note on Monday, December 9th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $3.00 price target on shares of Lucid Diagnostics in a report on Thursday, November 14th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Lucid Diagnostics presently has an average rating of “Buy” and an average target price of $3.63.

Lucid Diagnostics Stock Down 0.5 %

The stock has a market cap of $50.01 million, a P/E ratio of -0.74 and a beta of 1.45. The firm’s 50-day moving average is $0.87 and its two-hundred day moving average is $0.85.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.